Table 1 Demographics and baseline characteristics of the participants
|  | P013 (N = 107) | Reference pertuzumab (N = 107) |
|---|---|---|
Age (years), Mean ± SD | 47.56 ± 10.31 | 44.35 ± 9.81 |
BMI (kg/m2), Mean ± SD | 28.27 ± 5.30 | 27.27 ± 4.38 |
BSA (m2), Mean ± SD | 1.79 ± 0.18 | 1.79 ± 0.18 |
IHC 2+, No. (%) | ||
 FISH+ | 3 (2.80) | 3 (2.80) |
 CISH+ | 6 (5.61) | 3 (2.80) |
IHC 3+, No. (%) | 98 (91.59) | 101 (94.39) |
ER/PR, No. (%) | ||
 ER and/or PR positive | 63 (58.88) | 64 (59.81) |
 ER and PR negative | 44 (41.12) | 43 (40.19) |
Type of breast cancer, No. (%) | ||
 Inflammatory | 6 (5.61) | 6 (5.61) |
 Locally advanced | 49 (45.79) | 48 (44.86) |
 Operable | 52 (48.60) | 53 (49.53) |
The largest dimension of the tumor size, median (Q1, Q3) | 45 (34, 65) | 45 (35, 63) |